Klinische Studien

Wir tragen dafür Sorge, dass die Qualität unserer medizinischen Leistungen auf dem neuesten Stand und auf hohem Niveau bleibt und ständig verbessert wird. Die Teilnahme an wissenschaftlichen Studien gewährleistet, dass aktuellstes Fachwissen unmittelbar in Ihre Behandlung einfließen kann.

Klinische Studien haben dazu beigetragen, dass es heute erfolgreiche Behandlungsmethoden für Tumorerkrankungen gibt, die früher unheilbar waren.

Wer als Patient an einer Studie teilnimmt, hilft aktiv mit, dass auch künftig Fortschritte in der Behandlung von Krebserkrankungen erzielt werden können.


Kongressbeiträge

2020

First interim results from Hyperion, a non-interventional study analysing the effectiveness of atezolizumab (atezo) monotherapy for locally advanced or metastatic non-small cell lung cancer (mNSCLC) after prior chemotherapy (CTx). Heigener D, Geßner C, Nusch A, Schichtl T, Schütte W, Hammerschmidt S, Henschke S, Schumann C, Reck M, Schulz H, Koszinowski S, Reinmuth N. DGHO Jahrestagung 2020 Abstract Book

ENLARGE Lung: Observational data on overall survival, safety and quality of life of 882 patients with locally advanced or metastatic (stage IIIB/IV) non-small cell lung cancer (NSCLC) treated with nivolumab in Germany. Schumann C, Gröschel A, Gütz S, Schulz H, Müller-Huesmann H, Liersch R, von der Heyde E, Waldenberger D, Sebastian M. DGHO Jahrestagung 2020 Abstract Book

Prophylaxis of chemotherapy-induced neutropenia with Lipegfilgrastim in patients with NSCLC: final results from the non-interventional study NADIR. Geßner C, Lück A, Schulz H, Losem C, Dresemann G, Grebhardt S, Harde J, Marschner N, Hipp J, Potthoff K. DGHO Jahrestagung 2020 Abstract Book

First results from INFINITY - A registry on decision making and clinical impact of biomarker-driven precision oncology in routine clinical practice. Martens U, Reiser M, Schirrmacher-Memmel S, Sellmann L, Decker T, Schneeweiss A, Schuler M, Bengsch F, Vannier C, Potthoff K, Marschner N, Kasenda B. DGHO Jahrestagung 2020 Abstract Book

Changes in treatment of patients with multiple myeloma in Germany - results from the MYRIAM registry. Engelhardt M, Knauf W, Lipke J, Reiser M, Dörfel S, Kortüm M, Schlag R, von der Heyde E, La Rosée P, Pfannes R, Houet L, Medinger T, Jänicke M, Marschner N, Dechow T, Einsele H. MYRIAM-Studiengruppe DGHO Jahrestagung 2020 Abstract Book

Influence of the treatment of immune thrombocytopenia (ITP) with Eltrombopag on the fatigue symptoms of ITP patients - Results of the third interim analysis of the German non-interventional study RISA. Meyer O, Stauch M, Kämpfe D, Schlag R, Reiser M, Stauch T, von der Heyde E, Josting A, Plath M, Ballerstädt N, Stark-Lorenzen P, Scheibenbogen C. DGHO Jahrestagung 2020 Abstract Book

Prognosis in patients with advanced pancreatic cancer and effectiveness of 1st-line treatments - a prognostic and comparative effectiveness study using propensity score weighting for patients treated with Gem+Nab vs. FOLFIRINOX from the TPK registry Hegewisch-Becker S, Reiser M, von der Heyde E, Bertram M, Hollerbach S H, Kreher S, Binninger A, Chiabudini M, Jänicke M, Marschner N. DGHO Jahrestagung 2020 Abstract Book

Treatment patterns of patients with BRAF-mutant metastatic colorectal cancer: Results from the German Tumor Registry Colorectal Cancer (TKK Registry). Zahn M-O, Dörfel S, Schnell R, Wolf T, Vehling-Kaiser U, Kruggel L, Jänicke M, Wetzel N, Marschner N, TKK registry group. DGHO Jahrestagung 2020 Abstract Book

Treatment outcome of patients with diffuse large B-cell lymphoma (DLBCL) in routine care who received standard chemoimmunotherapy with MabThera® compared to patients treated with a rituximab biosimilar in first line therapy. Weide R, Burkhard O, Steinmetz T, Schnell R, Vehling-Kaiser U, Koenigsmann M, Ehscheidt P, Müller L, Otremba B, Wierecky J, Tamm I, Hensel M, Knoblich J, Feiten S, Chakupurakal G, Friesenhahn V, Kleboth K, Köppler H, Lutschkin J, Lutz C, Thomalla J, van Roye C, Heymanns J. DGHO Jahrestagung 2020 Abstract Book

Treatment reality of patients with multiple myeloma 1995-2018 in Germany Weide R, Steinmetz T, Schnell R, Maasberg M, Müller L, Burkhard O, Braun U, Ehscheidt P, Tamm I, Rendenbach B, Feiten S. DGHO Jahrestagung 2020 Abstract Book

FIND: a phase II study to evaluate the efficacy of erdafitinib in FGFR-altered NSCLC. Nogova L, Malchers F, Hillmer A M, Merkelbach-Bruse S, Pinto A, Scheel A H, Siemanowski J, Ueckeroth F, Scheffler M, Hummel H-D, Kern J, Wermke M, Kolbe M, Grohe C, Stratmann J, Sebastian M, Trummer A, Weber J-P, Westphal T, Michels S, Koleczko S, Sueptitz J, Keser E, Kron A, Riedel R, Abdulla D S Y, Zadoyan G, Sweiti H, Santiago-Walker A, Rothe A, Draube A, Sandler A, Rodermann E, Linck D, Thomas R K, Büttner R, Wolf J. DGHO Jahrestagung 2020 Abstract Book

KRAS mutations in never-smoker NSCLC patients: Defining a new patient subgroup. Scheffler M, Nogova L, Michels S, Holzem A, Chanra T, Abdulla D S Y, Koleczko S, Merkelbach-Bruse S, Fassunke J, Kron A, Scheel A H, Ihle M A, Heydt C, Westphal T, Weber J-P, Fischer R N, Riedel R, Kaminsky B, Draube A, Rothe A, Kambartel K-O, Hillmer A, Büttner R, Wolf J. DGHO Jahrestagung 2020 Abstract Book

Disease management of patients with immune thrombocytopenie - results of a representative retrospective survey in Germany. AS Kubasch, J Kisro, J Heßling, H Schulz, HJ Hurtz, M Klausmann, A Ehrnsperger, U Platzbecker. EHA 2020 Abstract Book

2019

Ibrutinib versus Placobo in patients with asymptomatic, treatment-naive early stage chronic lymphocytic leukomiaa (CLL):Primary endpoint results of the phase 3 double-blind randomized CLL12 TRIAL. Langerbeins P, Bahlo J, Rhein C, Gerwin H, Cramer P, Fürstenau M, Al-Sawaf O, von Tresckow J, Fink AM, Kreuzer KA, Vehling-Kaiser U, Tausch E, Müller L, Eckart MJ, Schlag R, Freier W, Gaska T, Balser C, Reiser M, Stauch M, Wendtner CM, Fischer K, Stilgenbauer S, Eichhorst B, Hallek M. EHA Library. Jun 16, 2019

Cytoreductive Treatment in 'Real Life' - Interim-Analysis of 434 Polycythemia Vera Patients in Germany. Carl C Crodel, Kathleen Jentsch-Ulrich, Lutz Jacobasch, Philipp Kiewe, Jens Kisro, Jörg Lipke, Siegfried W Prenninger, Marcel Reiser, Regine Wunschel, Andreas Hochhaus, Florian H Heidel. Blood (2019) 134 (Supplement_1): 1672

Evaluation of EGFR inhibitor-mediated acneiform skin toxicity within the double-blind randomized EVITA trial: a thorough gender-specific analysis using the WoMo score. Maria R Gaiser, Sylvie Lorenzen, Kirsten Merx, Jörg Trojan, Janja Ocvirk, Thomas J Ettrich  Salah-Eddin Al-Batran, Holger Schulz, Nils Homann, Hans-Peter Feustel, Michael Schatz, Melanie Kripp, Nadine Schulte, Steffen Heeger, Soetkin Vlassak, Winfried Koch, Ralf-Dieter Hofheinz. Cancer Med 2019 Aug;8(9):4169-4175

Ibrutinib versus placebo in patients with asymptomatic, treatment-naïve early stage chronic lymphocytic leukemia (CLL): primary endpoint results of the phase 3 double-blind, placebo-controlled randomized CLL12 trial. Langerbeins P, Bahlo J, Rhein C, Gerwin H, Cramer P, Fürstenau M, Al-Sawaf O, von Tresckow J, Fink A-M, Kreuzer K-A, Vehling-Kaiser U, Tausch E, Müller L, Eckart M J, Schlag R, Freier W, Gaska T, Balser C, Reiser M, Stauch M, Wendtner C-M, Fischer K, Stilgenbauer S, Eichhorst B, Hallek M. Deutsche CLL Studiengruppe DGHO Jahrestagung 2019 Abstract Book

Treatment of immunethrombocytopenia (ITP) with Revolade - results of the 2nd interim analysis of the German non-interventional trial RISA. Meyer O, Stauch M, Kämpfe D, Schlag R, Reiser M, Dörfel S, von der Heyde E, Josting A, Lipke J, Ballerstädt N, Michels K. DGHO Jahrestagung 2019 Abstract Book

Implementation of a molecular tumor board in clinical decision making at the medical center University of Freiburg. Hoefflin R, Wehrle J, Becker H, Reiser M, Metzger P, Hess M, Mehmed L, Rawluk J, Heiland D H, Erbes T, Schaefer H, Heeg S, Hettmer S, Boeker M, Werner M, Duyster J, Peters C, Botzenhart E M, Brummer T, Fritsch R, Dierks C, Miething C, Illert L, Lassmann S, Boerries M, von Bubnoff N. DGHO Jahrestagung 2019 Abstract Book

2nd-line treatment and outcome in patients with locally advanced or metastatic pancreatic cancer - data from the TPK clinical cohort study. Hegewisch-Becker S, Lerchenmüller C, Reiser M, Zacharias S, Hamm D, Jaenicke M, Marschner N, for the TPK Registry Group. DGHO Jahrestagung 2019 Abstract Book

Patient-reported outcomes (PRO) on the use of Ruxolitinib (RUX) in myelofibrosis (MF): data from the JAKoMo phase IV trial. Koschmieder S, Schulte C, Reiser M, Hansen R, Koenigsmann M, Geer T, Gröschl B, Großer S, Koehler M. DGHO Jahrestagung 2019Abstract Book

Patients with metastatic non-small cell lung carcinoma and targetable oncogenic molecular alterations in Germany. Treatment and first outcome data from the prospective German registry CRISP (AIO-TRK-0315). Griesinger F, Eberhardt W E E, Nusch A, Reiser M, Zahn M-O, Marschner N, Jänicke M, Fleitz A, Spring L, Sahlmann J, Karatas A, Hipper A, Weichert W, Waller C F, Reck M, Christopoulos P, Sebastian M, Thomas M. DGHO Jahrestagung 2019 Abstract Book

ith multiple myeloma in Germany - first patient-reported outcomes data from MYRIAM, the prospective, national, intersectoral cohort study for treatment and outcome of myeloma patients. Engelhardt M, Knauf W, Lipke J, Zahn M-O, Dörfel S, Bittrich M, Reiser M, Sauer A, Aubele P O, La Rosée P, Houet L, Medinger T, Jänicke M, Marschner N, Dechow T, Einsele H. MYRIAM-Studiengruppe DGHO Jahrestagung 2019 Abstract Book

Real-world evidence: interim analysis of efficacy in 628 patients with stage IIIB/IV non-small cell lung cancer (NSCLC) treated with Nivolumab after prior chemotherapy in a national, prospective, non-Interventional study (ENLARGE-Lung). Sebastian M, Gröschel A, Gütz S, Schulz H, Müller-Huesmann H, Schulte C, Wünsch V, Schumann C. DGHO Jahrestagung 2019 Abstract Book

Prophylaxis of chemotherapy-induced neutropenia and febrile neutropenia with long-acting G-CSF in patients treated with chemotherapy in Germany: results of the epidemiological cross-sectional survey “G-CSF Day”. Egerer G, Uleer C, Klausmann M, Lück A, Schröder J, Schulz H, Fichter C, von der Heyde E, Voss P, Worth G, Burbeck M, Sahlmann J, Potthoff K. DGHO Jahrestagung 2019 Abstract Book

Treatment reality of patients with multiple myeloma 2012-2017 in Germany Weide R, Burkhard O, Braun U, Steinmetz T, Ehscheidt P, Schnell R, Tamm I, Müller L, Feiten S. DGHO Jahrestagung 2019 Abstract Book

Patients with marginal zone lymphoma: characteristics, treatment reality and outcome data from the German prospective TLN Registry. Knauf W, Abenhardt W, Koenigsmann M, Maintz C, Sandner R, Zahn M-O, Schnell R, Houet L, Tech S, Jänicke M, Marschner N. TLN-Studiengruppe DGHO Jahrestagung 2019 Abstract Book

2018

Disease management of patients with immune thrombo-cytopenia - Results of a representative retrospective survey in Germany. Kubasch AS Kisro J, Heßling J, Schulz H, Hurtz HJ, Klausmann M, Ehrnsperger A, Platzbecker U. EHA Library. annual congress E. Jun 11, 2018; 219320; Abstract PF675

Personalized clinical decision making through implementation of a molecular tumorboard at the comprehensive cancer center Freiburg. Hoefflin R, Geißler AL, Fritsch R, Claus R, Wehrle J, Metzger P, Reiser M, Mehmed L, Fauth L, Heiland DH, Erbes T, Stock F, Csanadi A, Miething C, Weddeling B, Meiss F, von Bubnoff D, Dierks C, Ge I, Brass V, Heeg S, Schäfer H, Boeker M, Rawluk J, Botzenhart EM, Kayser G, Hettmer S, Busch H, Peters C, Werner M, Duyster J.1, Brummer T, Börries M, Lassmann S, von Bubnoff N. Oncology Research and Treatment (DGHO Jahrestagung 2018) - Band 41, Supplement 4, September 2018

Safety and efficacy of the thrombopoietin receptor agonist Eltrombopag in patients with chronic Immune Thrombocytopenia (cITP) in routine healthcare – results of the 1st interim analysis of the non-interventional study RISA. Meyer O, Reiser M, Dörfel S, Schlag R, Kämpfe D, Welslau M, Losem C, Zahn MO, von der Heyde E, Ehrnsperger A. Oncology Research and Treatment (DGHO Jahrestagung 2018) - Band 41, Supplement 4, September 2018

Survival of patients with metastatic solid tumours who received their treatment in community-based oncology group practices is longer compared to registry data and comparable to randomized controlled trials (RCT). Weide R, Chakupurakal G, Feiten S, Friesenhahn V, Kleboth K, Köppler H, Lutschkin J, Thomalla J, van Roye C, Oswald B, Reimann B, Lorentz C, Rendenbach B, Laubenstein HP, Braun U, Hünermund K, Ehscheidt P, Reiser M, Heymanns J. Oncology Research and Treatment (DGHO Jahrestagung 2018) - Band 41, Supplement 4, September 2018

Molecular testing, frequency of molecular alterations and targeted 1st-line treatment of patients with non-small cell lung carcinoma in Germany. Results from the prospective German Registry CRISP (AIO-TRK-0315). Griesinger F, Eberhardt W, Nusch A, Reiser M, Bernhardt C, Marschner N, Jänicke M, Fleitz A, Spring L, Sahlmann J, Karatas A, Hipper A, Weichert W, Rittmeyer A, Bischoff H, Waller CF, Sebastian M, Thomas M. Oncology Research and Treatment (DGHO Jahrestagung 2018) - Band 41, Supplement 4, September 2018

Real life data of 601 patients from the QoliXane pancreatic cancer study. Schönherr C, Götze TO, zur Hausen G, Reichart A, Pauligk C, Schlag R, Siegler G, Dörfel S, Aldaoud A, Hahn L, Schubert J, Zahn MO, Höffkes HG, Reiser M, Koenigsmann M, Blau W, Uhlig J, Homann N, Trojan J, Al-Batran SE. Oncology Research and Treatment (DGHO Jahrestagung 2018) - Band 41, Supplement 4, September 2018

Carfilzomib in combination with lenalidomide and dexamethasone or carfilzomib in combination with dexamethasone alone in patients with multiple myeloma who have received at least one prior therapy: Interim results of the non-interventional CARO study. Knauf W, Ammon A, Uhlig J, Merling M, Hurtz HJ, Vannier C.4, Schulz H, Marschner N, Riedt T, Potthoff K. Oncology Research and Treatment (DGHO Jahrestagung 2018) - Band 41, Supplement 4, September 2018

Nab-paclitaxel in combination with carboplatin as first line therapy for patients with stage IIIB/IV NSCLC in the real-world setting: Interim results of the NEPTUN study. Dechow T, Riera-Knorrenschild J, Schulz H, Janssen J, Chiabudini M, Koszinowski S, Potthoff K, Runkel E. Oncology Research and Treatment (DGHO Jahrestagung 2018) - Band 41, Supplement 4, September 2018

Prospective multicenter analysis of health status and quality of life in patients with immunodeficiencies receiving intravenous immunoglobulin G (IgG) substitution in oncology group practices in Germany (LQ-IgG). Weide R, Schnell R, Schardt C, Koenigsmann M, Otremba B, Zahn M, Wierecky J, Hünermund K, Hensel M, Klausmann M, Hartenstein R, Ehscheidt P, Feiten S. Oncology Research and Treatment (DGHO Jahrestagung 2018) - Band 41, Supplement 4, September 2018

Efficacy and safety of Trifluridin/Tipiracil (FTD/TPI) (Lonsurf®) in patients with metastatic colorectal cancer (CRC) in clinical routine use Cao J, Wiesweg M, Fuchs M, Stein A, Karthaus M, Lettmaier S, Kretzschmar A, Draube A, Ettrich T, Rüssel J, Müller C, Rafiyan MRR, Borchert K, Schuler M, Kasper S. Oncology Research and Treatment (DGHO Jahrestagung 2018) - Band 41, Supplement 4, September 2018

Interim Results of the Observational Study Caro: Twice Weekly Carfilzomib Is a Convenient Treatment Option for Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy. Knauf W, Ammon A, Uhlig J, Merling M, Hurtz HJ, Vannier C, Schulz H, Marschner N, Riedt T, Potthoff K. Blood 2018 132:5662

Comorbidities Such As Thromboembolic Events Significantly Worsen Patient-Reported Quality of Life (QoL) and Symptoms in Myeloproliferative Neoplasms (MPN) - Data from the Bioregistry of the German Study Group for MPN (GSG-MPN). Isfort S, Stegelmann F, Klausmann M, Schulz H, Hollburg W, Al-Ali HA, Goethert JR, Heidel FH, Maintz C, Haenel M, Platzbecker U, Hansen R, Keszei A, Gecht J, Kricheldorf K, Kaifie A, Crysandt M, Gezer D, Griesshammer M, Brümmendorf TH, Döhner K, Koschmieder S. Blood 2018 132:4292

Real life data of 601 patients from the QoliXane pancreatic cancer study. Schoenher C, Goetze TO, zur Hausen G, Reichart A, Pauligk C, Schlag R, Siegler GM, Doerfel S, Aldaoud A, Hahn L, Schubert JEA, Zahn MO, Hoeffkes HG, Reiser M, Koenigsmann M, Blau W, Uhlig J, Homann N, Trojan J, Al-Batran SE. Journal of Clinical Oncology 2018 36:15_suppl, e16248-e16248

Clinical efficacy and safety of regorafenib (REG) in the treatment of metastatic colorectal cancer (mCRC) in daily practice in Germany: Final results of the prospective multicentre non-interventional RECORA study. Schulz H, Janssen J, Strauss UP, Langen M, Dworschak KU, Fiala-Buskies S, Bokemeyer C, on behalf of the RECORA Investigators. ASCO GI Kongress San Francisco Abstract Januar 2018

Real Life Data of 601 patients from the QoliXane Pancreatic Cancer Study. Schönherr C, Götze TO, zur Hausen G, Reichart A, Pauligk C, Schlag R, Siegler G, Dörfel S, Aldaoud A, Hahn L, Schubert J, Zahn MO, Höffkes HG, Reiser M, Koenigsmann M, Blau W, Uhlig J, Homann N, Trojan J, Al-Batran SE. DHGO Abstract 2018

2017

Final results from an observational study (PLATEAU) of adult patients treated with romiplostim for primary immune thrombocytopenia (ITP) in routine clinical practice in Germany. Reiser M, Welslau M, Josten K, Dietzfelbinger H, Kuhn A.
EHA 2017 Abstract E1449

Retrospective analysis of the disease management of patients with immune thrombocytopenia. Platzbecker U, Heßling J, Hurtz HJ, Schulz H , Josting A, Hauch U, von der Heyde E, Dengler J, Tummes D, Plath M, Becker M, Welslau M, von Depka Prondzinski M. DGHO Poster 30.09.2017

Molecular testing and first-line treatment of patients with NSCLC. First results from the German CRISP study (AIO-TRK-0315). Griesinger F, Eberhardt WEE, Nusch A, Reiser M , Losem C, Ketzler-Henkel S, Zahn M-O, Marschner N, Jaenicke M, Fleitz A, Spring L, Sahlmann J, Karatas A, Hipper A, de Wit M, Metzenmacher M, Waller CF, Kern J, Weichert W, Sebastian M, Thomas M. WLCC Abstract 2017, DKK Abstract 2017, DGP Abstract 2017

Molecular testing, frequency of molecular alterations and first-line treatment of patients with non-small cell lung carcinoma (NSCLC) in Germany. First results from the prospective German Registry CRISP (AIO-TRK-0315) Griesinger F.Eberhardt W.E.Nusch A. Reiser M .Losem C.Ketzler- Henkel S. Zahn M.-O Marschner N.Jänicke M.Fleitz A.Spring L.Sahlmann J. Hipper A.Karatas A.de Wit M.Metzenmacher M.Waller C.F.Kern J. Weichert W.Sebastian M.Thomas M. DGHO abstract
Oncol Res Treat 2017;40(suppl 3): 1-168 V508

Cisplatin vs. carboplatin in routine treatment of advanced non-small cell lung cancer - results from the prospective German TLK cohort study Verschuer U. Schnell R .Zahn M.-O.Eggert J.Binninger A.Spring L.Jänicke M. Marschner N.
Oncol Res Treat 2017;40(suppl 3): 1-168 V718

Metastatic Pancreatic Cancer: real Life Data from the German Quality of Life and translational research on pancreatic cancer study (QoliXane) Reichart A. Al-Batran S.-E. Schönherr C. Zur Hausen G. Pauligk C. Schöttger B. Siegler G. Dörfel S. Aldaoud A. Hahn L. Schubert J. Waidmann O. Trojan J. Höffkes H.-G. Schnell R. Königsmann M. Blau W.Uhlig J.Homann N. Götze T.O. 1
Oncol Res Treat 2017;40(suppl 3): 1-168 P536

High age and high frequency of treatment switch in CML patients outside of clinical trials: interim results of the German CML VI trial Kohlbrenner K. 1 , Arnecke L. 1 , Fabarius A. 1 , Bieber R. 1 , Voskanyan A. 1 , Reiser M . 2 , Fenchel K. 3 , Schmidt E. 4 , Göhler T. 5 , Kühn R.B. 6 , Depenbusch R. 7 , Azeh I. 8 , Kleeberg U.R. 9 , Hansen R. 10 , Hänel M. 11 , Anhuf J. 12 , Jehner P. 13 , Baerlocher G.M. 14 , Brümmendorf T.H. 15 , Ehninger G. 16 , Hasford J. 17 , Heim D. 18 , Hossfeld D.K. 19 , Kolb H.-J. 20 , Krause S.W. 21 , le Coutre P. 22 , Nerl C. 23 , Neubauer A. 24 , Niederwieser D. 25 , Tesch H. 26 , Hochhaus A. 27 , Hehlmann R. 1
Oncol Res Treat 2017;40(suppl 3): 1-168 V763

Efficacy of different immunoglobulin doses in the prevention of severe and serious infections in patients with secondary immunodeficiencies - results from a multicenter observational study with Privigen® Ehlers H.-U. 1 , Innig G. 2 , Otremba B. 3 , Plath M. 4 , Slawik H.R. 4 , Â¥. 5 , Weide R. 6 , Pfründer D. Reiser M. 2 , Fenchel K. 3 , Schmidt E. 4 , Göhler T. 5 , Kühn R.B. 6 , Depenbusch R. 7 , Azeh I. 8 , Kleeberg U.R. 9 , Hansen R. 10 , Hänel M. 11 , Anhuf J. 12 , Jehner P. 13 , Baerlocher G.M. 14 , Brümmendorf T.H. 15 , Ehninger G. 16 , Hasford J. 17 , Heim D. 18 , Hossfeld D.K. 19 , Kolb H.-J. 20 , Krause S.W. 21 , le Coutre P. 22 , Nerl C.   23 , Neubauer A. 24 , Niederwieser D. 25 , Tesch H. 26 , Hochhaus A. 27 , Hehlmann R. 28 , Saußele S. 1 , for the German CML study group
Oncol Res Treat 2017;40(suppl 3): 1-168 P846

Correlation between the IgG plasma concentrations and the incidence of infections in patients with chronic lymphocytic leukemia (CLL) under treatment with Privigen® Otremba B. 1 , Haslbauer F. 2 , Reiser M . 3 , Weide R. 4 , Pfründer D. 5 P313 Retrospective analysis of the disease management of patients with immune thrombocytopenia Platzbecker U. 1 , Heßling J. 2 , Hurtz H.-J. 3 , Schulz H . 4 , Josting A. 5 , Hauch U. 6 , von der Heyde E. 7 , Dengler J. 8 , Tummes D. 9 , Plath M. 10 , Becker M. 11 , Welslau M. 12 , von Depka Prondzinski M.
Oncol Res Treat 2017;40(suppl 3): 1-168 P577

Bevacizumab (Bev)-based combinations across treatment lines in patients (pts) with metastatic colorectal cancer (mCRC) - interim results from a German non-interventional study (KORALLE) Eggers E. 1 , Uhlig J. 2 , Reichert D. 3 , Wein A. 4 , Schulz H . 5 , Beringer A. 6 , Arnold D.
Oncol Res Treat 2017;40(suppl 3): 1-168

Systemic palliative treatment and outcome in later lines in patients with metastatic colorectal cancer - Real-life data from the clinical Tumour Registry Colorectal Cancer (TKK) Schnell R . 1 , Uhlig J. 2 , Eggers E. 3 , Jänicke M. 4 , Fleitz A. 4 , Wetzel N. 4 , Marschner N. 5 , for the TKK registry group
Oncol Res Treat 2017;40(suppl 3): 1-168 P587

EHA FINAL RESULTS FROM AN OBSERVATIONAL STUDY (PLATEAU) OF ADULT PATIENTS TREATED WITH ROMIPLOSTIM FOR PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) IN ROUTINE CLINICAL PRACTICE IN GERMANY Author(s): Marcel Reiser , Manfred Welslau , Klaus Josten , Hermann Dietzfelbinger ,Anja Kuhn (Abstract release date: May 18, 2017) EHA Learning Center. Reiser M . EHA May 18, 2017; 181225

Clinical efficacy and safety of regorafenib (REG) in the treatment of metastatic colorectal cancer (mCRC) in daily practice in Germany: Interim results of the prospective multicentre noninterventional RECORA study .
Holger Schulz , Jan Janssen , Uwe P. Strauss , Markus Langen , Marcel Frey , Sabine Fiala-Buskies ,
Journal of Clinical Oncology 35, no. 4_suppl (February 2017) 769-769.

2016

Correlation between efficacy of the intravenous immunoglobulin preparation IgPro10 and IgG plasma concentrations achieved in secondary immunodeficiencies (SID). Reiser M, Otremba B, Plath M, Slawik HR, Pfründer D. 17th ESID Meeting (European Society of Immunodeficiencies) Barcelona 2016

Systemic palliative treatment in patients with metastatic colorectal cancer tested for their (K)RAS mutation status - Real-life data from the clinical Tumour Registry Colorectal Cancer (TKK) Zahn M.O. 1 , Schnell R . 2 , Karcher A. 3 , Schnitzler M. 4 , Wetzel N. 4 , Fleitz A. 4 , Marschner N. 5 , for the TKK registry group
Oncol Res Treat 2016;39(suppl 3):1-294: V171

Overall survival of 4865 patients with metastatic solid tumours treated in German routine practice - combined results from four prospective, multicentre cohort studies Marschner N. 1 , Potthoff K. 2 , Schnell R . 3 , Tesch H. 4 , Zahn M.-O. 5 , Hegewisch- Becker S. 6 , Jänicke M. 2 , iOM-Registry group Onkol. Schwerpunktpraxis HH Eppendorf, Hamburg, Germany
Oncol Res Treat 2016;39(suppl 3):1-294: V174

Treatment and survival of patients with advanced pancreatic cancer in community-based oncology group practices 2012 - 2015 Weide R. 1 , Burkhard O. 2 , Reiser M . 3 , Ehscheidt P. 4 , Feiten S.
Oncol Res Treat 2016;39(suppl 3):1-294: P868

Prophylaxis of chemotherapy-induced neutropenia with Lipegfilgrastim in patients with lung cancer: results from an interim analysis of the non-interventional study NADIR Potthoff K. 1 , Lück A. 2 , Frost N. 3 , Losem C. 4 , Weide R. 5 , Schulz H.
Oncol Res Treat 2016;39(suppl 3):1-294:P949

Parenteral nutrition support for patients with advanced pancreatic cancer - interim results from the sub-project "PaNut" of the Pancreatic Cancer Registry (TPK) Hegewisch-Becker S. 1 , Wolf T. 2 , Reiser M . 3 , Scheiner-Sparna R. 4 , Hamm D. 4 , Marschner N. 5 , for the TPK Registry Group 1 Onkologische Schwerpunktpraxis Hamburg Eppendorf, Hamburg, Germany, 2 BAG/Onkologische Gemeinschaftspraxis, Dresden, Germany, 3 Praxis internistischer Onkologie und Hämatologie, Köln, Germany, 4 iOMEDICO, Freiburg i. Br., Germany, 5 Praxis für Interdisziplinäre Onkologie & Hämatologie, Freiburg i. Br., Germany
Oncol Res Treat 2016;39(suppl 3):1-294: P869 Â Â

Utilisation of facilitated subcutaneous immunoglobulin treatment (HYQvia) in patients with SID: Preliminary data from the SIGNS registry Reiser M. 1 , Fasshauer M. 2 , Borte M. 2 , Baumann U. 3 , Gold R. 4 , Pittrow D. 5 , Huscher D. 6 , Stangel M. 7 , Sommer C. 8 , Otto G.P. 9 , Hensel M.
Oncol Res Treat 2016;39(suppl 3):1-294: P956

Prophylaxis of chemotherapy-induced neutropenia with Lipegfilgrastim in patients with Non-Hodgkin-Lymphoma (NHL): results from an interim analysis of the non- interventional study NADIR Fietz T. 1 , Wolff T. 2 , Schulz H . 3 , Sandner R. 4 , Reichert D. 5 , Hurtz H.-J. 6 , Müller J. 7 , Grebhardt S.
Oncol Res Treat 2016;39(suppl 3):1-294: P950

2015

Privigen® in secondary immunodeficiencies - interim analysis of a multicenter non-interventional study in Germany Plath M.1, Slawik H.R.1, Reiser M .2, Otremba B.3, Pfründer D.
Oncol Res Treat 2015;38(suppl 5):1-288 P253 -

Cytogenetic and molecular responses in German patients with chronic-phase chronic myeloid leukemia (CP-CML) in a prospective observational study (SIMPLICITY) Repp R.1, Hehlmann R.2, Linde H.3, Reiser M .4, Tesch H.5, Foreman A.6, Schreiner L.7, Hillig G.
Oncol Res Treat 2015;38(suppl 5):1-288 P451 -

Application of Rituximab in Maintenance (RIM) therapy in Follicular Lymphoma (FL) in routine clinical practice - final results of a non-interventional study (NIS) in Germany Dührsen U.1, Dieing A.2, Reiser M .3, Prange-Krex G.4, Jentsch-Ullrich K.5, Lück A.6, Porowski P.7, Schwinger U.8, Broszeit-Luft S.9, Klawitter S.10, Krumm K.10, Lerchenmüller C.
Oncol Res Treat 2015;38(suppl 5):1-288 P473

Implementation of RAS testing in patients with metastatic colorectal cancer in German outpatient cancer centers - data from the clinical TKK registry Schnell R .1, Trarbach T.2, Broszeit-Luft S.3, Musch R.4, Frank M.2, Kopfmann S.2, Jänicke M.2, Marschner N.5, for the TKK Registry Group
Oncol Res Treat 2015;38(suppl 5):1-288 V394

Relevance of neo- or adjuvant pretreatment in patients with metastatic colorectal cancer treated with FOLFIRI plus bevacizumab as first-line treatment - data from the prospective TKK registry Schnell R. 1, Trarbach T.2, Broszeit-Luft S.3, Musch R.4, Wetzel N.2, Kopfmann S.2, Jänicke M.2, Marschner N.5, for the TKK Registry Group
Oncol Res Treat 2015;38(suppl 5):1-288 V395

The need for psychooncological support in breast cancer patients: A longitudinal study. Ralf R. Reichelt , Christian M. Kurbacher , Roland Schnell
Journal of Clinical Oncology 33, no. 15_suppl

SORAVE: Phase I study for the treatment of relapsed solid tumors with the combination of sorafenib and everolimus. Lucia Nogova , Christian Mattonet , Matthias Scheffler , Marc Christiaan Allardt Bos , Masyar Gardizi , Irini Papachristou , Noemi Muthen , Denis Rokitta , Martina Kinzig , Fritz Soergel , Uwe Fuhr , Deniz Kahraman , Carsten Kobe , Kerstin Rhiem , Peter Mallmann , Roland Schnell , Ildiko Katay , Max Schlaak , Markus Dietlein , Juergen Wolf
Journal of Clinical Oncology 33, no. 15_suppl (May 2015) 2550-2550.

2014

Genotyping upper gastrointestinal cancer in daily clinical care. Thomas Zander , Michael Kloth , Shahram Zoghi , Laura Groneck , Birgit Cremer , Roland Schnell , Marcel Reiser , Jutta Benz , Tom Luedde , Achim Rothe , Yon-Dschun Ko , Andreas Draube , Stefan Paul Moenig , Juergen Wolf , Arnulf H Hölscher , Reinhard Buettner
Journal of Clinical Oncology 32, no. 15_suppl

Management of secondary immunodeficiencies with immunoglobulins (IG) under clinical practice conditions: update 2014 Hensel M. 1 , Stangel M. 2 , Gold R. 3 , Borte M. 4 , Faßhauer M. 4 , Pittrow D. 5 , Huscher D. 6 , Baumann U. 7 , Kirch W. 5 , Reiser M . 8 , SIGNS Studiengruppe
Oncol Res Treat 2014;37(suppl 5):1-313 P188

Effectiveness of bevacizumab beyond progression in patients with metastatic colorectal cancer - data from the clinical TKK registry Schnell R . 1 , Musch R. 2 , Broszeit-Luft S. 3 , Harde J. 4 , Kopfmann S. 4 , Jänicke M. 4 , Marschner N.
Oncol Res Treat 2014;37(suppl 5): 1-313 V332 Â Â

Cancer patient self-assessment of symptoms and complaints, and their computer-assisted documentation Schnell R. , Heirich P., Hellmann M ., Eisenblätter C., Schulz H. pioh Frechen, Frechen, Germany
Oncol Res Treat 2014;37(suppl 5): 1-313 P539

Treatment of relapsed/refractory multiple myeloma patients with lenalidomide/dexamethasone in routine clinical practice Schwarzer A. 1 , Frühauf S. 2 , Königsmann M. 3 , Schnell R . 4 , Reeb M. 5 , Heits F. 6 , Tirier C. 7 , Prange-Krex G. 8 , Knauf W. 9 , Bachinger A. 10 , Weiligmann C. 11 , Hoppe G. 11 , Glasmacher A. 12 , Schmidt B.
Oncol Res Treat 2014;37(suppl 5): 1-313 P871

RET rearrangement in adenocarcinoma of the lung Michels S. 1 , Schultheis A. 2 , Scheffler M. 1 , Rosner T. 1 , Merkelbach- Bruse S. 2 , Heukamp L. 2 , Engel-Riedel W. 3 , Serke M. 4 , Krüger S. 5 , Benedikter J. 6 , Gerigk U. 7 , Schulte W. 8 , Draube A . 9 , Ko Y.D. 10 , Büttner R. 2 , Wolf J. 1 , Lung Cancer Group Cologne
Oncol Res Treat 2014;37(suppl 5): 1-313 V32

PROCAPP: A randomized, open-label phase III trial comparing mapisal and urea hand-foot cream as prophylaxis for capecitabine-induced hand-foot skin reaction (HFSR) in patients (pts) with gastrointestinal (GI) tumors or breast cancer – A study of the AIO Quality of Life Working Group.
Deniz Gencer , Andreas Schneeweiss , Holger Schulz , Michael Stahl , Susanna Hegewisch-Becker , Luisa Mantovani Loeffler , Ursula Kronawitter , Georg Bolz , Jochen Potenberg , Salah-Eddin Al-Batran , Ralf Hofheinz
Journal of Clinical Oncology 32, no. 15_suppl (May 2014) 9631-9631.

2013

Overall survival of ALK translocation positive NSCLC patients treated with and without crizotinib. A retrospective analysis within the Network Genomic Medicine Bos M. 1 , Gardizi M. 1 , Heukamp L. 2 , Nogova L. 1 , Merkelbach- Bruhse S. 2 , König K. 2 , Zander T. 3 , Schildhaus H.-U. 2 , Fricke R. 4 , Krieg V. 4 , Scheffler M. 1 , Serke M. 5 , Schnell R . 6 , Schulz H. 6 , Töpelt K. 3 , Panse J. 7 , Schmitz S. 8 , Severin K. 9 , Steinmetz T. 9 , Gerigk U. 10 , Brettner S. 11 , Hecker E. 12 , Reiser M. 6 , Katay I. 6 , Kaufmann T. 13 , Ko Y.D. 14 , Buchenroth M. 15 , Kruis W. 16 , Schlesinger A. 17 , Laskowski U. 18 , Maintz C. 19 , Vogt J. 20 , Randerath W.J. 21 , Konrad F. 22 , Hekmat K. 23 , Krüger S. 24 , Kambartel K. 25 , Galetke W. 26 , Hünerlitürkoglu A.-N. 27 , Thomas R. 28 , Büttner R. 2 , Wolf J. 1 , Netzwerk Genomische Medizin
Onkologie 2013;36(suppl 7):1-289 V116

Current development of the Network Genomic Medicine in lung cancer Bos M. 1 , Heukamp L. 2 , Gardizi M. 1 , König K. 2 , Merkelbach-Bruhse S. 2 , Zander T. 3 , Scheffler M. 4 , Albus K. 2 , Schildhaus H.-U. 5 , Fassunke J. 5 , Künstlinger H. 5 , Kleine M. 2 , Binot E. 2 , Nogova L. 1 , Mattonet C. 1 , Serke M. 6 , Panse J. 7 , Schnell R . 8 , Schulz H. 8 , Töpelt K. 4 , Schlesinger A. 9 , Krüger S. 10 , Kambartel K. 11 , Reiser M. 12 , Behringer D. 13 , Gerigk U. 14 , Schulte W. 15 , Diet F. 16 , Randerath W.J. 17 , Brettner S. 18 , Ko Y.D. 19 , Buchenroth M. 20 , Benz J. 21 , Severin K. 22 , Schmitz S. 22 , Steinmetz T. 22 , Mainka D. 22 , Dietze L. 22 , Kaufmann T. 23 , Konrad F. 24 , Hekmat K. 25 , Thomas R. 26 , Büttner R. 2 , Wolf J. 1 , Netzwerk Genomische Medizin Onkologie 2013;36(suppl 7):1-289 V603

Current management of secondary immunodeficiency (SID) under clinical practice conditions Hensel M. 1 , Gold R. 2 , Baumann U. 3 , Borte M. 4 , Stangel M. 5 , Fasshauer M. 4 , Pittrow D. 6 , Huscher D. 7 , Kirch W. 6 , Reiser M . 8 , SIGNS Study Onkologie 2013;36(suppl 7):1-289 V711

Overcoming EGFR-TKI resistance in EGFR-mutated lung cancer Gardizi M. 1 , Scheffler M. 1 , Bos M. 1 , Geist T. 2 , Heukamp L. 3 , Nogova L. 1 , Töpelt K. 1 , Fernandez-Cuesta L. 4 , Culmann H. 5 , Kaminsky B. 6 , Panse J. 7 , Becker C. 7 , Mattonet C. 1 , Serke M. 8 , Schmitz S. 9 , Schnell R. 1 , Galetke W. 10 , Hekmat K. 1 , Büttner R. 3 , Wolf J.
Onkologie 2013;36(suppl 7):1-289 V120

Association of PIK3CA mutations and age with the occurence of second primary lung cancer (SPLC).

Marc Christiaan Allardt Bos , Masyar Gardizi , Matthias Scheffler , Lucia Nogova , Thomas Zander , Lukas Carl Heukamp , Hans-Ulrich Schildhaus , Sabine Merkelbach-Bruse , Jana Fassunke , Elke Binot , Andreas Schlesinger , Thomas Geist , Kato Kambartel , Roland Schnell , Holger Schulz , Dirk M. Behringer , Monika Serke , Stephan H. Schmitz , Winfried Randerath , Juergen Wolf
Journal of Clinical Oncology 31, no. 15_suppl (May 2013) 1589-1589.

2012

Predictive diagnostics for response to therapy of chemotherapy associated anemia with darbepoetin alfa +/- intravenous iron in cancer patients: PFAD. Â Steinmetz HT, Kuhr K, Hellmich M, Heinz M, Neise M, Mittermüller J, Tessen HW, Reiser M , Severin K, Schmitz S, Tessen W. ESMO Kopenhagen Abstract Oct 2012

Outcome of elderly DLBCL patients with 6xCHOP-14 and 8 rituximab (R) applications given over an extended period (SMARTE-R-CHOP-14 trial of the DSHNHL). Niels Murawski , Gerhard Held , Samira Zeynalova , Carsten Mueller , Viola Poeschel , Andreas Viardot , Mathias Haenel , Ulrich Keller , Marcel Reiser , Marita Ziepert , Norbert Schmitz , Michael Pfreundschuh ,
Journal of Clinical Oncology 30, no. 15_suppl (May 2012) 8025-8025.

Evidence for rituximab (R) underdosing in subpopulations of elderly patients with DLBC: Results of the RICOVER-60 study of the DSHNHL. Michael Pfreundschuh , Carsten Mueller , Samira Zeynalova , Gerhard Held , Viola Poeschel , Carsten Zwick , Marcel Reiser , Eva Lengfelder , Hjalmar B. Steinhauer , Christina Limmroth , Norbert Schmitz , Niels Murawski ,
Journal of Clinical Oncology 30, no. 15_suppl (May 2012) 8024-8024.

Management of secondary immunodeficiencies with immunoglobulins (IG) under clinical practice conditions. Marcel Reiser , David Pittrow , Martin Stangel , Ralf Gold , Michael Borte , Maria Fasshauer , Wilhelm Kirch , Doerte Huscher , Ulrich Baumann , Manfred Hensel
DOI: 10.1200/jco.2014.32.15_suppl.e17596 Journal of Clinical Oncology 32, no. 15_suppl

IMPACT study: A phase II-III clinical study with the immunomodulator MGN1703 in patients with advanced colorectal carcincoma . Marina Tschaika , Hans-Joachim Schmoll , Jorge Riera-Knorrenschild , Dieter Nitsche , Jorg Trojan , H. Kröning , Fritz Albert Maiwirth , Marcel Reiser , Matthias Schroff , Ekaterina Weith , Manuel Schmidt , Burghardt Wittig Journal of Clinical Oncology Feb 2012

Role of radiotherapy for elderly DLBCL patients in the rituximab (R) era: Final results of the RICOVER-60-no-rx study of the DSHNHL . Gerhard Held , Niels Murawski , Marita Ziepert , Viola Poeschel , Carsten Zwick , Marcel Reiser , Sibylla Wilhelm , Tobias Gaska , Michael Heike , Joerg Schubert , Norbert Schmitz , Markus Loeffler , Christian Ruebe , Michael Pfreundschuh ,
Journal of Clinical Oncology 30, no. 15_suppl (May 2012) 8022-8022

Clinical characteristics and natural history of patients with squamous cell lung carcinoma with FGFR1 amplification . Marc Christiaan Allardt Bos , Masyar Gardizi , Lukas Carl Heukamp , Hans-Ulrich Schildhaus , Lucia Nogova , Yon-Dschun Ko , Andreas Schlesinger , Michael Brockmann , Monika Heidi Serke , Ulrich Gerigk , Khosro Hekmat , Erich Stoelben , Marcel Reiser , Walburga Engel-Riedel , Roland Schnell , Stephan H. Schmitz , Konrad Frank , Reinhard Buettner , Juergen Wolf , Thomas Zander
Journal of Clinical Oncology 30, no. 15_suppl (May 2012) 1533-1533.

Frequency and clinical characterization of NSCLC patients harboring PIK3CA mutations identified within a regional screening network . Masyar Gardizi , Matthias Scheffler , Lukas Carl Heukamp , Marc Christiaan Allardt Bos , Kerstin Albus , Birgit Hayn , Yon-Dschun Ko , Andreas Schlesinger , Michael Brockmann , Monika Heidi Serke , Ulrich Gerigk , Khosro Hekmat , Erich Stoelben , Marcel Reiser , Roland Schnell , Stephan H. Schmitz , Konrad Frank , Reinhard Buettner , Jurgen Wolf , Thomas Zander
Journal of Clinical Oncology 30, no. 15_suppl (May 2012) 10526-10526.

Regional screening network for characterization of the molecular epidemiology of non-small cell lung cancer (NSCLC) and implementation of personalized treatment. Thomas Zander , Lukas Carl Heukamp , Marc Christiaan Allardt Bos , Jana Fassunke , Christian Mattonet , Sabine Merkelbach-Bruse , Yon-Dschun Ko , Andreas Schlesinger , Michael Brockmann , Monika Serke , Ulrich Gerigk , Khosro Hekmat , Walburga Engel-Riedel , Erich Stoelben , Marcel Reiser , Holger Schulz , Stephan H. Schmitz , Konrad Frank , Reinhard Buettner , Juergen Wolf
Journal of Clinical Oncology 2012 30, no. 18_suppl

CNS-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation (HD-ASCT) for CNS relapse of aggressive lymphomas: Final analysis of a phase II study. Agnieszka Korfel , Gerald Illerhaus , Mathias Haenel , Robert Moehle , Roland Schroers , Thomas Elter , Marcel Reiser , Martin H. Dreyling , Jan Eucker , Christian Winfried Scholz , Bernd Metzner , Alexander Roeth , Josef Birkmann , Uwe S. Schlegel , Peter Martus , Eckhard Thiel , Lars Fischer
Journal of Clinical Oncology 30, no. 15_suppl (May 2012) 8031-8031.

Non-interventional study of rituximab in the treatment of Chronic Lymphocytic Leukaemia (CLL NIS): first interim results Reiser, M. 1 , Hensel, M. 2 , Hoesl, M. 3 , Janssen, J. 4 , Jentsch- Ullrich, K. 5 , Koenigsmann, M. 6 , Lück, A. 7 , Schwarzer, A. 8 , Tschechne, B. 9 , Hechenbichler, K. 10 , Kellershohn, K. 11 , Maschmeyer, G.
Onkologie 2012;35(suppl 6):1-259 P723

Romiplostim for the treatment of adults with primary Immune Thrombocytopenia (ITP) in routine clinical practice in Germany - Interim results from an observational study (PLATEAU) Welslau, M. 1 , Reiser, M. 2 , Illmer, T. 3 , Schlag, R. 4 , Josten, K. 5 , Dietzfelbinger, H. 6 , Tschechne, B. 7 , Schaffrik, M. 8 , Sölch, J.-P
Onkologie 2012;35(suppl 6):1-259 P740

Management of secondary immunodeficiency (SID) under clinical practice conditions Hensel, M. 1 , Baumann, U. 2 , Gold, R. 3 , Borte, M. 4 , Fasshauer, M. 4 , Pittrow, D. 5 , Kirch, W. 5 , Huscher, D. 6 , Stangel, M. 7 , Reiser, M . 8 , for the SIGNS group Onkologie, Köln, Germany
Onkologie 2012;35(suppl 6):1-259 P758

SORAVE: Phase I study for the treatment of relapsed solid tumours with the combination of sorafenib and everolimus Nogová, L. 1 , Mattonet, C. 1 , Scheffler, M. 1 , Bos, M. 1 , Gardizi, M. 1 , Papachristou, I. 1 , Rokitta, D. 2 , Fuhr, U. 2 , Kinzig, M. 3 , Sörgel, F. 3 , Kahraman, D. 4 , Kobe, C. 4 , Rhiem, K. 5 , Mallmann, P. 5 , Schnell, R. 6 , Katay, I. 7 , Schlaak, M. 8 , Dietlein, M. 4 , Wolf, J.
Onkologie 2012;35(suppl 6):1-259 V681 Â Â

Results of the first interim analysis of the CARMA study to investigate efficacy and safety profile of catumaxomab in clinical practice.

Volker Kunzmann , Jalid Sehouli , Barbara Schmalfeldt , Pauline Wimberger , Christian M. Kurbacher , G.-F. Tempelhoff , Udo J. Vanhoefer , P. Ebeling , F. Breuer , Holger Schulz , Manfred Welslau , Dominique Finas , Jaqueline Sagasser , M. Kiehl , S. Fruehauf
Journal of Clinical Oncology 2012 30, no. 15_suppl

© 2020 pioh frechen, pioh köln zentrum, pioh köln nord